The global chemical and pharmaceutical company Merck is working intently to strengthen its capabilities in the pharmaceutical sector.

The company, whose main areas of expertise are liquid crystal and LED, has also been continuing its commitment to introduce new drugs, starting with the anticancer drug ‘Erbitux (cetuximanb),’ the immune-oncology PD-L1 inhibitor ‘Bavencio (avelumab)’ that was co-developed with Pfizer, to the recently approved multiple sclerosis treatment 'Mavenclad (cladribine).’

Dailypharm met with Javed Alam, the General Manager of Merck Biopharma Korea, who has celebrated his 2nd year at the company, to hear about Merck’s vision in the healthcare business.